Iran is considering a short-term pause to shipments through the Strait of Hormuz to avoid testing a US blockade and scuppering a fresh round of peace talks, according to a person familiar with the Tehran’s deliberations. The potential pause reflects a desire to avoid immediate escalation at a sensitive diplomatic juncture as Washington and Tehran sort logistics for another face-to-face meeting, th...
Iran is considering a short-term pause to shipments through the Strait of Hormuz to avoid testing a US blockade and scuppering a fresh round of peace talks, according to a person familiar with the Tehran’s deliberations. The potential pause reflects a desire to avoid immediate escalation at a sensitive diplomatic juncture as Washington and Tehran sort logistics for another face-to-face meeting, the person said, asking not to be identified as the deliberations are private. The Iranian embassy in the UK and the foreign ministry in Tehran didn’t immediately respond to requests for comment. The US and Iran are weighing further negotiations to extend a ceasefire, Bloomberg reported Monday, as President Donald Trump presses ahead with a naval blockade to curb the Islamic Republic’s oil exports. The objective is to hold fresh talks before the truce expires next week. Holding back maritime activity for several days is seen as one possible, pragmatic step to prevent an incident that could undermine the fragile efforts to revive discussions, people familiar with the matter said. Iran’s calculus remains fluid, they said. The country’s Islamic Revolutionary Guard Corps could shift course quickly, for example, by trying to show that the US blockade can be challenged without consequence, a move that would risk undercutting the diplomatic track. Oil traders are laser-focused on any transits through the crucial Strait of Hormuz, with Tehran blocking almost all non-Iranian shipping and the US now conducting its own blockade. Until now, Iran has been pretty much the only country to send oil through the waterway during the conflict. Read More: Hormuz Shipping Collapses Again as US Starts Own Blockade A pause would underscore the tightrope Iran is walking as it seeks to project resolve without provoking confrontation that may foreclose a diplomatic opening.
Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before stocks turned around before noon, and it was an off-and-running, risk-off Monday, with all the major market indices posting strong gains and finishing the day higher. Once again, the small-cap ... Here Are Tuesday’s Top Wall Street Analyst Resear...
Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before stocks turned around before noon, and it was an off-and-running, risk-off Monday, with all the major market indices posting strong gains and finishing the day higher. Once again, the small-cap ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and Mor
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More 24/7 Wall St.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More 24/7 Wall St.
hapabapa/iStock Editorial via Getty Images Lucid Group ( LCID ) has priced a $300M public offering of common stock, part of a larger $1.05B capital raise that includes investments from Uber ( UBER ) and Saudi Arabia’s Public Investment Fund. The offering is expected to close on or about April 15, 2026, subject to customary closing conditions. BofA Securities ( BAC ) is acting as the sole underwrit...
hapabapa/iStock Editorial via Getty Images Lucid Group ( LCID ) has priced a $300M public offering of common stock, part of a larger $1.05B capital raise that includes investments from Uber ( UBER ) and Saudi Arabia’s Public Investment Fund. The offering is expected to close on or about April 15, 2026, subject to customary closing conditions. BofA Securities ( BAC ) is acting as the sole underwriter for the underwritten offering. As previously announced earlier today, Uber ( UBER ) will increase its purchase commitment to at least 35,000 Lucid vehicles designed exclusively for use as part of Uber's future global robotaxi service. Uber has also committed to an additional $200M investment in Lucid, raising Uber's total investments to $500M to date. Ayar Third Investment has also committed a new investment of $550M of convertible preferred stock. Together with the gross proceeds from the underwritten offering, the total raise for these transactions is expected to be ~$1.05B. The company also provided preliminary financial results for the quarter ended March 31, 2026, expecting revenue of $280M to $284M (vs. $433.77M consensus estimate ) and loss of $985M-$1B. As of March 31, 2026, Lucid had approximately $3.16B of total liquidity. LCID shares rose 4.3% premarket at $9.64. More on Lucid Lucid: Supplier Snags Not A Problem Lucid Group, Inc. (LCID) Presents at Bank of America Global Automotive Summit Transcript Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q4 2025 Update Lucid appoints Silvio Napoli as CEO to drive growth Lucid rallies after landing new investments from Uber and the Saudi Arabian sovereign wealth fund
Tech giant Microsoft (NASDAQ:MSFT) trades at $370.87 as of writing, down 23.14% year-to-date. Our price target is $488.47, implying roughly 31.71% upside over the next 12 months. Our recommendation is buy, with a 90% confidence level. Metric Value Current Price $370.87 24/7 Wall St. Price Target $488.47 Upside 31.71% Recommendation BUY Confidence Level 90% The ... This Will Be Microsoft’s Price Ne...
Tech giant Microsoft (NASDAQ:MSFT) trades at $370.87 as of writing, down 23.14% year-to-date. Our price target is $488.47, implying roughly 31.71% upside over the next 12 months. Our recommendation is buy, with a 90% confidence level. Metric Value Current Price $370.87 24/7 Wall St. Price Target $488.47 Upside 31.71% Recommendation BUY Confidence Level 90% The ... This Will Be Microsoft’s Price Next Year
AgEagle Aerial Systems ( UAVS ) said on Tuesday its subsidiary EagleNXT had formed a U.S.-based joint venture, ThirdEye USA, with Israel’s ThirdEye Systems, alongside a $10M strategic investment. The venture will focus on counter-drone products for U.S. and Canadian markets and operate from Allen, Texas. EagleNXT will hold a 51% stake in ThirdEye USA, with ThirdEye Systems owning 49%, and will app...
AgEagle Aerial Systems ( UAVS ) said on Tuesday its subsidiary EagleNXT had formed a U.S.-based joint venture, ThirdEye USA, with Israel’s ThirdEye Systems, alongside a $10M strategic investment. The venture will focus on counter-drone products for U.S. and Canadian markets and operate from Allen, Texas. EagleNXT will hold a 51% stake in ThirdEye USA, with ThirdEye Systems owning 49%, and will appoint three of five managers. The company said the venture is expected to accelerate development of integrated counter-UAS and aerial intelligence solutions. ThirdEye USA is expected to begin operations by May 2026. Shares +2.66%. More on AgEagle Aerial Systems AgEagle Aerial Systems reports FY results Financial information for AgEagle Aerial Systems
(RTTNews) - Albertsons Companies (ACI) reported a fourth quarter net loss of $480.8 million or $0.94 per share compared to net income of $171.8 million or $0.29 per share, a year ago. Net loss during the fourth quarter included the $599.8 million charge, net of tax, or $1.18 per
(RTTNews) - Albertsons Companies (ACI) reported a fourth quarter net loss of $480.8 million or $0.94 per share compared to net income of $171.8 million or $0.29 per share, a year ago. Net loss during the fourth quarter included the $599.8 million charge, net of tax, or $1.18 per
Shares of Travere Therapeutics ( TVTX ) and Ligand Pharmaceuticals ( LGND ) traded higher in the premarket on Tuesday after the FDA approved a label expansion for their jointly developed kidney disease therapy Filspari. Travere Therapeutics ( TVTX ) climbed ~43% after announcing the FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS), a rare proteinuric kidney disorder that can ...
Shares of Travere Therapeutics ( TVTX ) and Ligand Pharmaceuticals ( LGND ) traded higher in the premarket on Tuesday after the FDA approved a label expansion for their jointly developed kidney disease therapy Filspari. Travere Therapeutics ( TVTX ) climbed ~43% after announcing the FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS), a rare proteinuric kidney disorder that can lead to kidney failure in both adults and children. The agency has approved the once-daily oral medication to reduce proteinuria in adults and children with FSGS without nephrotic syndrome, making it the first and only FDA-approved medication for the condition, the California-based biotech said. Ligand Pharma ( LGND ) added that under a collaboration with Travere ( TVTX ), it is entitled to a 9% royalty on global net sales of Filspari, which, according to the company, is the most commonly prescribed FDA-approved therapy for IgA nephropathy, a rare progressive kidney disease. The companies won full U.S. approval for Filspari, also known as sparsentan, for IgAN in 2024 after getting accelerated approval a year ago. More on Travere Therapeutics, Ligand Pharmaceuticals Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS - Slideshow Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model Ligand gains new Buy from BofA on high-margin, less risky narrative Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates